Author: MyHairline Editorial Team Editorial review: MyHairline medical content review. Named clinician reviewer pending verified reviewer relationship and crawlable bio. Last updated: May 2026
Educational use only. This article is not medical advice. The Myhairline.ai analyzer is an educational classification tool and does not diagnose, treat, or prescribe. Treatment decisions belong with a board-certified dermatologist or qualified clinician.
Last February, a 31-year-old software developer named Marcus in Austin told me he'd spent three hours on a Saturday morning with 14 browser tabs open, toggling between Keeps and Hims product pages, Reddit threads, and YouTube reviews. "I kept waiting for someone to just tell me the actual difference," he said. "Every comparison site felt like an ad for one of them." His monthly budget was $30, his Norwood stage was roughly a 2.5 based on photos he'd uploaded to our analyzer, and he wanted to know if the $6-per-month price gap between the two services translated into anything medically meaningful.
The short answer he needed, and the one this article will defend: for FDA-approved medications, it almost never does. The longer answer is more interesting, and more useful.
The Boring Truth About Identical Active Ingredients
If you're comparing Keeps vs Hims for finasteride or minoxidil, you're comparing two delivery trucks carrying the same cargo. Finasteride is finasteride. Minoxidil is minoxidil. One milligram of generic finasteride from Keeps performs identically to one milligram from Hims, which performs identically to one milligram from your local CVS. The FDA doesn't grant one telehealth brand a special version of the molecule.
This isn't a controversial claim. It's pharmacology 101. But it's the claim that gets buried in almost every comparison article, because acknowledging it up front makes the rest of the comparison less dramatic.
So what are you actually choosing between? Pricing structure. Telemedicine experience. Formulation options (topical finasteride, combination sprays, that sort of thing). Shipping reliability. How the consultation works. Whether a real prescriber reviews your case with any rigor, or whether you're basically checking boxes in a web form and a script auto-generates.
Those differences are real. They're just not pharmacological differences.
What the Medications Actually Do (A Quick Refresher)
Finasteride is a 5-alpha-reductase inhibitor, FDA-approved for male androgenetic alopecia. It blocks the conversion of testosterone to DHT, the hormone most responsible for miniaturizing hair follicles in genetically susceptible men. The landmark 1998 trial by Kaufman et al. in the Journal of the American Academy of Dermatology demonstrated significant hair count stabilization and modest regrowth versus placebo over two years (Kaufman et al., 1998).
Minoxidil is a topical vasodilator. Its exact mechanism in hair growth still isn't fully understood, which is a refreshingly honest thing to admit about a drug that's been on the market for decades. The 2002 trial by Olsen et al. in the same journal showed 5% topical minoxidil outperformed 2% and placebo in men with androgenetic alopecia (Olsen et al., 2002). Available as foam or solution, 2% or 5%.
Dutasteride blocks both type I and type II 5-alpha-reductase (finasteride only blocks type II). It's FDA-approved for benign prostatic hyperplasia, not hair loss, so its use for alopecia is off-label. Some clinicians prescribe it when finasteride alone isn't cutting it.
Here's the thing: neither Keeps nor Hims invented any of these drugs. They're subscription wrappers around generics.
Where the Services Actually Diverge
Strip away the Instagram marketing and the differences between Keeps and Hims come down to a handful of practical dimensions:
Monthly cost at standard dosing. Both services adjust pricing frequently, run promotions, and bundle products in ways designed to make direct comparison annoying. As of this writing, the gap for standalone generic finasteride is modest (single-digit dollars per month). But combination products, topical formulations, and "complete kits" widen the spread. Always compare the per-active-ingredient cost, not the package price.
Clinical oversight. Both platforms offer telemedicine consultations, but the depth varies. Some patients report thorough intake questionnaires and follow-up messaging with a prescriber. Others describe something closer to a vending machine with a medical license attached. The quality of clinical oversight matters more than which logo is on the bottle, and it's the hardest variable to evaluate from a product page.
Formulation variety. Hims has pushed harder into combination topical products (finasteride plus minoxidil sprays, for example). Keeps has historically leaned toward standard oral finasteride and topical minoxidil sold separately. Whether a combination topical is better for you depends on your tolerance for oral medications, your pattern of loss, and your prescriber's judgment.
State licensure and prescribing scope. Both operate through networks of licensed prescribers, but availability and the specific clinician you're matched with can vary by state.
Ancillary products. Shampoos, biotin gummies, supplements. These are margin-builders for the companies. The evidence base for most ancillary hair-loss supplements is thin to nonexistent compared to the FDA-approved medications. Don't let a $12 shampoo add-on influence which service you pick for your finasteride prescription.
The Device Question (A Separate Comparison Entirely)
Both Keeps and Hims occasionally offer or reference low-level laser therapy devices. This is a different category of comparison entirely, and conflating it with the medication question muddies the analysis.
Consumer LLLT devices (caps, helmets, combs) use red-spectrum light, typically 650 to 680 nanometers, to stimulate follicular activity. The 2014 trial by Jimenez et al. in the American Journal of Clinical Dermatology showed modest hair count improvements versus sham devices (Jimenez et al., 2014). "Modest" is the operative word. The effect sizes are smaller than for finasteride or minoxidil, and the trial evidence is less extensive.
Most consumer devices are FDA-cleared through the 510(k) pathway, which demonstrates substantial equivalence to a predicate device, not primary efficacy. That's a lower bar than the PMA (premarket approval) process used for new drugs. It doesn't mean devices are useless. It means the evidence base is thinner, and you should calibrate your expectations accordingly.
If you're comparing a specific Keeps device to a specific Hims device, the meaningful variables are: number of laser diodes, total energy delivered per session, treatment protocol, warranty, and whether the device's specific configuration has been studied (most haven't been independently).
Why Most "Best" Lists Get This Wrong
Think of it like comparing two gas stations on opposite sides of the same highway. Both sell 87-octane unleaded. One has cleaner bathrooms. The other is three cents cheaper per gallon. A review that declares one gas station's fuel "superior" is either confused or selling you something.
The "top 10 hair loss treatments" format is structurally biased toward brands with bigger affiliate payouts. My genuinely opinionated take: if a comparison article doesn't acknowledge early on that the active ingredients are identical across FDA-approved generics, it's a commercial wearing an editorial costume.
Meaningful comparison requires holding variables constant. Same patient profile (pattern, stage, sex, age). Same use case (starting therapy vs. maintenance). Same duration. Same outcome measure (hair count? cosmetic satisfaction? both?). Articles that bounce between patient types, toss in before-and-after photos with different lighting, and cite single testimonials as evidence aren't comparing anything. They're performing comparison.
Making the Actual Decision
For Marcus in Austin, the decision eventually came down to this: he wanted oral finasteride, he wanted the cheapest monthly price, and he wanted a prescriber who would actually look at his photos before writing the script. He picked the service that met those three criteria. It happened to be Keeps, but Hims would have delivered the same molecule.
Your version of that decision might weight different factors. A woman seeking topical-only therapy is in a different position than a man comfortable with oral finasteride. Someone with rapid Norwood 3-vertex progression might need a more aggressive protocol than someone with stable, mild temporal recession. (For a fuller picture of how staging works, see The Norwood Scale: Complete Guide to Male Pattern Hair Loss Stages.)
The most useful question isn't "Keeps or Hims?" It's "What active ingredient does my situation call for, and which service delivers it at a price and clinical oversight level I'm comfortable with?"
For PRP (platelet-rich plasma), the 2019 Journal of Dermatological Treatment meta-analysis found a small but statistically significant aggregate effect, though with substantial heterogeneity across studies. It's a reasonable adjunct for some patients, but it's in a different evidence tier than finasteride or minoxidil, and neither Keeps nor Hims is the primary channel for PRP anyway.
Common Questions
Are branded telemedicine services more effective than generic medication from a pharmacy? No. For FDA-approved medications, the active ingredient is pharmacologically identical regardless of where you buy it. You're paying for convenience, consultation, and shipping, not a better version of the drug.
Which has stronger trial evidence, a laser device or a medication? Medications win this one clearly. Finasteride and minoxidil have substantially more replicated, higher-quality trial evidence than any consumer laser device. LLLT has trial-level support but smaller effect sizes (Jimenez et al., 2014).
Does the Myhairline.ai analyzer diagnose hair loss? No. It's an educational classification tool. It does not diagnose, treat, or prescribe. A clinical diagnosis requires examination by a board-certified dermatologist.
Can I use both minoxidil and finasteride together? Many clinicians prescribe them in combination. The mechanisms are different (vasodilation vs. DHT inhibition), so they can be complementary. Discuss this with your prescriber.
Are the treatment outcomes discussed here guaranteed? No. Every treatment has documented variability in patient response. No medication, procedure, or device guarantees regrowth. Anyone claiming otherwise is overselling.
Should I choose based on price alone? Price is a legitimate factor, but clinical oversight quality matters too. A service that rubber-stamps every prescription without reviewing your history isn't saving you money if it leads to an inappropriate treatment plan.
How long do I need to use these medications before seeing results? Most dermatologists advise at least 6 to 12 months of consistent use before evaluating efficacy. Early shedding in the first few weeks is common with minoxidil and doesn't indicate failure.
Continue Reading
This article is part of the Comparisons & Decision-Making cluster on Myhairline.ai. The pillar overview is The Norwood Scale: Complete Guide to Male Pattern Hair Loss Stages, and the cluster hub is Comparisons & Decision-Making Cluster Hub.
Within this cluster:
- Irestore Vs Capillus: a focused reference on irestore vs capillus.
- Microneedling Vs Prp Hair Growth Effectiveness Comparison: a focused reference on microneedling vs prp hair growth effectiveness comparison.
- Diffuse Thinning Vs Male Pattern Baldness: a focused reference on diffuse thinning vs male pattern baldness.
Related from other clusters:
- Medication For Hair Loss: Complete Guide: a focused reference on medication for hair loss. (from the Non-Surgical Treatments cluster).
- Fue Hair Transplant Denver: Complete Guide: a focused reference on fue hair transplant denver. (from the Hair Transplant Cost & Process cluster).
Key References
Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Journal of the American Academy of Dermatology. 1998;39(4):578-589.
Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology. 2002;47(3):377-385.
Jimenez JJ, Wikramanayake TC, Bergfeld W, et al. Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss. American Journal of Clinical Dermatology. 2014;15(2):115-127.
Hamilton JB. Patterned loss of hair in man: types and incidence. Annals of the New York Academy of Sciences. 1951;53(3):708-728.
Norwood OT. Male pattern baldness: classification and incidence. Southern Medical Journal. 1975;68(11):1359-1365.